` CRIS (Curis Inc) vs S&P 500 Comparison - Alpha Spread

CRIS
vs
S&P 500

Over the past 12 months, CRIS has underperformed S&P 500, delivering a return of -68% compared to the S&P 500's +14% growth.

Stocks Performance
CRIS vs S&P 500

Loading
CRIS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CRIS vs S&P 500

Loading
CRIS
S&P 500
Difference
www.alphaspread.com

Performance By Year
CRIS vs S&P 500

Loading
CRIS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Curis Inc vs Peers

S&P 500
CRIS
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Curis Inc
Glance View

Market Cap
13.1m USD
Industry
Biotechnology

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.

CRIS Intrinsic Value
5.56 USD
Undervaluation 81%
Intrinsic Value
Price
Back to Top